BPC-157
Pentadecapeptide studied for tissue protection and repair models.
Category · RecoveryMech 7/10
View ProductAll pathwaysEmerging Limited Limited Emerging Moderate
Metabolic & endocrine signaling systems
Recovery, Sleep & Performance Research Pathway
Restoration and adaptive signaling.
This pathway groups peptides studied across recovery, sleep, and performance-related signaling, drawing from repair biology and the GH axis.
System Overview
The biological system this pathway studies.
Recovery and adaptive performance depend on soft-tissue repair, growth-hormone pulse biology, sleep architecture, and mitochondrial resilience under load. This pathway groups peptides studied across these overlapping systems in restoration and adaptation research.
Educational research context · not medical advice
Why This Pathway Matters
Performance and recovery rely on tissue restoration, GH-axis signaling, and cellular resilience.
This pathway groups research into how peptides influence soft-tissue repair, growth hormone pulse biology, and mitochondrial resilience. Together these mechanisms shape how the body adapts to load and restores baseline function in research models.
Tissue restoration
Soft-tissue and inflammatory recovery research.
GH-axis modulation
GH/IGF-1 pulse biology and recovery signaling.
Cellular resilience
Mitochondrial-targeted research compounds.
Educational research context · not medical advice
Research Progression Model
3 biological phases · click to explore
1
Research Phase 1
Tissue Restoration
Research focus
Compounds studied in soft-tissue and inflammatory recovery research.
Studied Compounds
BPC-157
Preclinical, limited human dataPositioned within the tissue repair and angiogenesis pathway, with reported activity at the vascular signaling and extracellular matrix interface in animal models.
Experimental injury windows of days to several weeks in animal modelsTB-500
Emerging preclinicalSits within the cell migration and tissue repair pathway, with reported influence on cytoskeletal dynamics that support repair-cell mobility.
Days to weeks in preclinical wound and repair models2
Research Phase 2
GH Axis Modulation
Research focus
Studied for GH/IGF-1 pulse research relevant to recovery models.
Studied Compounds
Ipamorelin
Low (acute hormonal only)Sits within the ghrelin/GH-axis signaling pathway, parallel to GHRH-driven pathways.
Acute studies; limited long-term outcome dataCJC-1295
Low to moderate (pharmacodynamic only)Sits within the GH/IGF-1 axis at the GHRH receptor signaling layer, with extended pharmacokinetic profile.
Days to weeks for pharmacodynamic studies3
Research Phase 3
Cellular Resilience
Research focus
Mitochondrial-targeted research compounds explored alongside performance models.
Studied Compounds
MOTS-c
Emerging preclinicalOperates as a mitochondria-to-nucleus signaling molecule within the cellular metabolic regulation pathway, sitting upstream of AMPK-dependent metabolic transcription programs.
Days to weeks in preclinical metabolic studiesSS-31
Moderate disease-specific clinical evidenceWithin the mitochondrial bioenergetics pathway, SS-31 is positioned upstream of downstream ATP-output endpoints, acting at the membrane-organization layer rather than at substrate input or transcriptional regulation.
Weeks to months in human disease-context trialsMechanism Flow
How signaling unfolds across the three research phases.
Phase 1 covers the initial biological process. Phase 2 maps the signaling cascades downstream. Phase 3 describes systemic effects studied in research models.
1
Phase 1 · Tissue restoration
- Soft-tissue and inflammatory recovery signaling
- Angiogenesis and cell-migration research
- Cytoprotective effects in injury models
2
Phase 2 · GH-axis modulation
- GHRH analog and ghrelin-receptor agonist research
- Pulsatile GH/IGF-1 response studies
- Recovery-relevant signaling in preclinical and clinical models
3
Phase 3 · Cellular resilience
- Mitochondrial-targeted compounds studied alongside performance models
- ETC stability and oxidative-stress modulation research
- Cellular energy signaling under stress
Studied Compounds
Compounds studied within this pathway.
Each entry summarizes the mechanism explored in research literature. Not a recommendation, dosing guide, or protocol.
- BPC-157Moderate
Studied for angiogenesis, growth factor modulation, and cytoprotection of gut/tendon tissue in animal models.
- TB-500Thymosin Beta-4 fragmentEmerging
Studied for actin sequestration, cell motility, and angiogenic signaling.
- IpamorelinLow
Studied for selective GHS-R activation with limited cortisol/prolactin effect.
- CJC-1295Low
Studied for sustained GHRH receptor activation.
- MOTS-cEmerging
Studied for AMPK activation, metabolic flexibility, and insulin sensitivity pathways.
- SS-31ElamipretideModerate
Binds cardiolipin in the inner mitochondrial membrane; studied for stabilizing electron transport chain integrity.
Research Observation Timeline Across This Pathway
Timeline patterns measured in studies of these compounds.
Every compound in this pathway has a primary study window described in the research literature. Windows below describe research observation periods only — not expected personal outcomes.
Preclinical, limited human data · 1Emerging preclinical · 2Low (acute hormonal only) · 1Low to moderate (pharmacodynamic only) · 1Moderate disease-specific clinical evidence · 1
- BPC-157Preclinical, limited human data
Measured in studies: Experimental injury windows of days to several weeks in animal models
Endpoint type · Histological and biomarker repair endpoints
- TB-500Emerging preclinical
Measured in studies: Days to weeks in preclinical wound and repair models
Endpoint type · Cellular migration and histological repair endpoints
- IpamorelinLow (acute hormonal only)
Measured in studies: Acute studies; limited long-term outcome data
Endpoint type · Hormonal biomarker endpoints
- CJC-1295Low to moderate (pharmacodynamic only)
Measured in studies: Days to weeks for pharmacodynamic studies
Endpoint type · Pharmacodynamic hormone endpoints
- MOTS-cEmerging preclinical
Measured in studies: Days to weeks in preclinical metabolic studies
Endpoint type · Biomarker and metabolic signaling endpoints
- SS-31Moderate disease-specific clinical evidence
Measured in studies: Weeks to months in human disease-context trials
Endpoint type · Biomarker, functional, and imaging endpoints
These windows reflect research observation periods only, not guaranteed personal outcomes.
Research Insights
What current research focuses on.
- Performance-framed research draws on adjacent recovery, GH-axis, and mitochondrial literature rather than standalone trials.
- Most direct human performance data is limited; mechanistic plausibility is stronger than outcome data.
- Sleep and restoration endpoints are studied indirectly through GH-axis and recovery markers.
Research Limitations
Where the evidence base is incomplete.
- Standalone performance trials in healthy athletic populations are scarce.
- Outcomes are confounded by training, sleep, and nutritional variables in research settings.
- Long-term effects of stacked recovery compounds are not well characterized.
Transparency note · evidence gaps disclosed for research integrity
Research Relationship Overview
How these compounds are studied together.
Each phase groups compounds with mechanistic overlap. The diagram shows which compounds are explored in combination within published research literature — not a recommended use strategy.
Pathway hubResearch phaseStudied compoundMechanistic overlap
DisclaimerThis visualization reflects research relationships and does not represent a recommended use strategy. Compounds shown here are studied together in research contexts only — this is not a protocol, dosing guide, or medical advice.
Catalog · Research compounds
Related Compounds Available
Compounds referenced in this pathway's research literature. Each links to its full Library profile — mechanism, evidence, and research context. Research use only.
Moderate
TB-500
Thymosin Beta-4 fragment
Synthetic fragment studied for cell migration and tissue remodeling.
Category · RecoveryMech 6/10
View ProductIpamorelin
Selective GH secretagogue studied for ghrelin receptor signaling.
Category · Growth Hormone AxisMech 7/10
View ProductCJC-1295
Long-acting GHRH analog studied in GH signaling research.
Category · Growth Hormone AxisMech 7/10
View ProductMOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Category · MitochondriaMech 7/10
View ProductSS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
Category · MitochondriaMech 8/10
View ProductFor research use only · Not for human consumption
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.